PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth under 50% of TRAW's 69.02%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-31.48%
Negative yoy D&A while TRAW is 4.35%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-66.70%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
10.78%
SBC growth while TRAW is negative at -3.06%. John Neff would see competitor possibly controlling share issuance more tightly.
-179.22%
Both reduce yoy usage, with TRAW at -140.39%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Negative yoy AP while TRAW is 226.19%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.10%
Both reduce yoy usage, with TRAW at -201.50%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
10.78%
Some yoy increase while TRAW is negative at -324.27%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-32.84%
Negative yoy CFO while TRAW is 5.99%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-1.01%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce yoy other investing while TRAW is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-1611.06%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Negative yoy issuance while TRAW is 13092.50%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.